Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

3-year results of thin flap aspherical LASIK for correction of high myopia

Poster Details

First Author: T. Manoilo UKRAINE

Co Author(s):    G. Parkhomenko                    

Abstract Details

Purpose:

To evaluate 3 year clinical results of thin flap aspherical LASIK for correction of high myopia.

Setting:

refractive department of “Noviy Zir” ophthalmosurgical clinic, Ukraine, Kyiv.

Methods:

This retrospective study evaluated 36 months results of thin flap aspherical LASIK for myopic and myopic astigmatism in 140 eyes of 75 patients. The LASIK flaps were created with the Carriaso-Pendular microkeratome and the ablation with Schwind Amaris®500 Excimer laser (SCHWIND eye-tech-solutions GmbH&Co. KG, Kleinosstheim, Germany). Clinical outcomes were evaluated for predictability, refractive outcome and safety. Mean preoperative SE was -7.2D ± 0.9D (-5.75 to -8.50D). Mean flap thickness was 105±7 µm.

Results:

At 12-month follow-up percentage of eyes achieving a UDVA of 0.5 were 100%, 0.8 - 95%, 1.0 - 93%. At 36 months of follow-up percentage of eyes achieving a UDVA of 0.5 were 100%, 0.8 - 92% , 1.0 - 91%. There was no loss of CDVA in 12 and 36 months. At 12 months of follow-up percentage of eyes that achieved within ±0.25D was 92%, ±0.5D was 95%, ±1.0D was 98%, ±1.25D was 100%. At 36 months of follow-up percentage of eyes that achieved within ±0.25D was 89%, ±0.5D was 93%, ±1.0D was 95%, ±1.5D was 100%. Only 6 eyes (4.3%) were retreated after 36 months due to regress of myopia.

Conclusions:

Thin flap aspherical LASIK using the Schwind Amaris® 500 excimer laser is safe and predictable and yields excelent and stable refractive results after high myopia correction. Refraction and visual acuity remain stable during follow-up.

Financial Disclosure:

NONE

Back to Poster listing